Do Rising Losses at uniQure (QURE) Reflect Strategic Investment or Escalating Cost Pressure?

• uniQure N.V. reported its third quarter 2025 financial results on November 10, with revenue rising to US$3.7 million from US$2.29 million a year earlier, accompanied by a net loss of US$80.53 million.
• An interesting insight from the announcement is that, despite higher quarterly revenue, the company’s losses deepened compared to the previous year, pointing to ongoing cost pressures or investment needs.
• We’ll now explore how uniQure’s widening quarterly losses and revenue changes could impact the key assumptions in its investment narrative.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

uniQure Investment Narrative Recap

To be a uniQure shareholder right now, you have to believe in the company’s ability to turn pioneering gene therapies, especially AMT-130 for Huntington’s disease, into commercial success. The latest earnings showed rising quarterly revenue but deepening losses, and while this may keep short-term investor focus on capital needs, it does not meaningfully shift the near-term catalyst: clarity around FDA approval prospects for AMT-130. However, the balance of risk still centers on regulatory timelines, with these financial results having limited direct impact on the biggest risks.

Among uniQure’s recent announcements, the November 3 update stands out: the FDA feedback that current AMT-130 data may not be enough for a BLA submission, clouding the path to a potential accelerated approval. This aligns directly with the narrative’s primary catalyst, as investor hopes are pinned on AMT-130’s acceptance; any regulatory delay, especially following deeper losses, puts additional pressure on the company’s cash runway and progress toward commercialization.

But despite the potential in gene therapy, there’s a significant risk that investors should be aware of if regulatory clarity for AMT-130 continues to...

Read the full narrative on uniQure (it's free!)

uniQure's narrative projects $306.4 million in revenue and $32.3 million in earnings by 2028. This requires 147.5% yearly revenue growth and a $249.9 million increase in earnings from -$217.6 million today.

Uncover how uniQure's forecasts yield a $75.09 fair value, a 148% upside to its current price.

Exploring Other Perspectives

Six different community opinions put uniQure’s fair value anywhere from US$13.55 to US$358.30 per share, reflecting starkly contrasting expectations. As you weigh these views, keep in mind the recent uncertainty around FDA approval for AMT-130 may influence how quickly revenue growth materializes, consider more than one scenario when looking ahead.

Explore 6 other fair value estimates on uniQure - why the stock might be a potential multi-bagger!

Build Your Own uniQure Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your uniQure research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.

No Opportunity In uniQure?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com